Genmab — August 2018

[MarsFars]

Det kan vi hurtigt give kælenavnet cami

[Bulder]

Det er nu et stykke tid siden. I daglig tale vil det hedde Cami-T - ikke at forveksle med camille-te.

[Raffles]

Nå for den! Så det først på hjemmesiden i går! Cami-T er til at huske:-)

[MarsFars]

Så er der lidt elastik tilbage op i kurs
i dag. Sjovt at se.

[Bulder]

@ Raffles https://en.wikipedia.org/wiki/Camidanlumab_tesirine

[E_L]

yes,it has been a bit under the radar here, shame on us https://adctherapeutics.com/downloads/1512998413.PDF

[E_L]

Completion dates for the 2 trials are actually june and august 2018, maybe we'll hear something about it next week and is that the reason for the website update

[E_L]

Nantes University Hospital will start a new Quadruplet study with carfilzomib, lenalidomide, dexamethasone and daratumumab to start and Maintenance with lenalidomide and dara / https://clinicaltrials.gov/ct2/show/NCT03606577?lupd_s=07%2F02%2F2018&lupd_d=30

[E_L]

This old Ofa CLL study is now completed. https://clinicaltrials.gov/ct2/history/NCT01039376?A=150&B=151&C=merged

[gentogen]

Det fremgår af hjemmesiden for HOVON, af CD20xCD3 rekrutterer fra foreløbig en klinik i Rotterdam (for lige at følge op på iagttagelsen fra tidligere)

[gentogen]

De har en undergruppe, der arbejder med 'first-in-man' studier

[E_L]

so you think this is GCT3013-01 @gentogen ?

[Raffles]

Thanks Bulder, EL and Gentogen. Your input is highly appreciated:-)

[gentogen]

Det ved jeg med sikkerhed, at det er. Se EHA 23 Abstract: PF637 fra juni måned, hvor det hedder, at "The clinical safety of DuoBody-CD3xCD20 (GEN3013) in patients with B cell malignancies will be assessed in a first-in-human study."

[gentogen]

CD3 BISPECIFIC ANTIBODY SCREEN IDENTIFIES CD20 AS THE MOST EFFICIENT TARGET FOR ELIMINATION OF B CELL MALIGNANCIES; PRE-CLINICAL EVALUATION OF DUOBODY-CD3XCD20
Author(s): Patrick Engelberts , Ida Hiemsta , Joyce Meesters , Bart De Jong , Theodora Salcedo , Sandra Verploegen , Edward van den Brink , Danita Schuurhuis , Sjeng Horbach , Aran Labrijn , Paul Parren , Janine Schuurman , Esther Breij
EHA Learning Center. Engelberts P. Jun 15, 2018; 215079

[gentogen]

one of the CD3xCD20 BsAbs showed extraordinary potency and outperformed the other CD20-targeting BsAb as well as CD3 BsAbs against all other B cell targets tested. This BsAb, designated DuoBody-CD3xCD20, was shown in vitro to only activate T cells in the presence of B cells and to induce potent T-cell-mediated cytotoxicity of B cell lymphoma cell line

[gentogen]

https://learningcenter.ehaweb.org/eha/2018/stockholm/215079/patrick.engelberts.cd3.bispecific.antibody.screen.identifies.cd20.as.the.most.html?f=ce_id=1346*ot_id=19042*media=3

[E_L]

excellent

[E_L]

you know, some still think PI stands for ProInvestor, but I think Helge really meant Private Investigator lol

[Helge_LarsenPI-redaktør]